Interleukin 2 targeted therapy in inflammatory bowel disease

Gut

Volumn 58, Issue 12, 2009, Pages 1705-1706

  Yarkoni, S ^a   Sagiv, Y ^a   Kaminitz, A ^b   Askenasy, N ^b  

^a Target In Ltd   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA;

B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; ENTERITIS; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY;

EID: 72549085536     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.175182     Document Type: Letter

References (24)

1. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-1574 (Pubitemid 44629204)
2. Shteingart S, Rapoport M, Grodzovski I, et al. Therapeutic potency of IL2-caspase3 targeted treatment in a murine experimental model of inflammatory bowel disease. Gut 2009;58:790-798
3. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003;170:3939-3943
4. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-674
5. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004;172:3983-3988
6. Yarkoni S, Kaminitz A, Sagiv Y, et al. Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle. Bioessays 2008;30:875-888
7. Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005;201:723-735 (Pubitemid 40395118)
8. Yokoyama Y, Fukunaga K, Fukuda Y, et al. Demonstration of low-regulatory CD25high+CD4+ and high-pro-inflammatory CD282CD4+ T-cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007;52:2725-2731 (Pubitemid 47373881)
9. Uhlig HH, Coombes J, Mottet C, et al. Characterization of Foxp3+CD4+CD25+ and IL-10- secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006;177:5852-5860
10. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25high T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868-1878 (Pubitemid 40824698)
11. Fantini MC, Becker C, Tubbe I, et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006;55:671-680
12. Yu QT, Saruta M, Avanesyan A, et al. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2007;13:191-199 (Pubitemid 46806228)
13. Makita S, Kanai T, Oshima S, et al. CD4-CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004;173:3119-3130
14. Mullin GE, Lazenby AJ, Harris ML, et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992;102:1620-1627
15. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-1090 (Pubitemid 29328123)
16. Toso C, Edgar R, Pawlick R, et al. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int 2009;22:182-191
17. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989;320:1420-1421 (Pubitemid 19138943)
18. Doering J, Begue B, Lentze MJ, et al. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 2004;53:1632-1638 (Pubitemid 39434107)
19. Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut 2004;53:1556-1558 (Pubitemid 39434092)
20. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007;56:293-303. (Pubitemid 46246220)
21. Itoh J, de La Motte C, Strong SA, et al. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001;49:35-41. (Pubitemid 32601877)
22. Sturm A, Leite AZ, Danese S, et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 2004;53:1624-1631 (Pubitemid 39434106)
23. Yarkoni S, Sagiv Y, Kaminitz A, et al. Targeted therapy to IL-2 receptor using diphtheria toxin and caspase-3 fusion proteins modulates regulatory T cells and ameliorates inflammatory colitis. Eur J Immunol 2009. doi:10.1002/eji.200839190.
24. Kuniyasu Y, Takahashi T, Itoh M, et al. Naturally anergic and suppressive CD25+CD4+ T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000;12:1145-1155 (Pubitemid 30618021)